积分兑换
关注公众号
收藏产品 产品详情
抗体来源（Source）
Anti-Rituximab Antibody is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.
种属（Species）
Mouse
亚型（Isotype）
Mouse IgG1/kappa
抗体类型（Antibody Type）
Recombinant Monoclonal
种属反应性（Reactivity）
Human
免疫原（Immunogen）
Rituximab.
特异性（Specificity）
Recognizes Rituximab specifically.
应用（Application）
ApplicationRecommended UsageELISA0.2-50 ng/mL纯度（Purity）
95% as determined by SDS-PAGE.
90% as determined by SEC-MALS.
纯化（Purification）
Protein A purified / Protein G purified
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 12 months under sterile conditions after reconstitution.
质量管理控制体系（QMS）
产品展示
电泳（SDS-PAGE）
Anti-Rituximab Antibody on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Anti-Rituximab Antibody (Cat. No. RIB-Y35c) is more than 90% and the molecular weight of this protein is around 135-155 kDa verified by SEC-MALS.
Report
活性（Bioactivity）-ELISA
Immobilized Rituximab at 1 μg/mL (100 μL/well) can bind Anti-Rituximab Antibody (Cat. No. RIB-Y35c) with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
Immobilized Rituximab at 2 μg/mL, add increasing concentrations of Anti-Rituximab Antibody (Cat. No. RIB-Y35c) in the 10% human serum and then add Anti-CD20, Human IgG1 at 5 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 100 ng/mL (QC tested).
Protocol
用户评价 发表评论
联系我们 
项目合作